About the Company
ptc is biopharmaceutical company focused on the discovery and development of orally-administered, proprietary small molecule drugs that target post-transcriptional control processes. while ptc’s discovery programs are directed at targets in multiple therapeutic areas, ptc is focusing particularly on the development and commercialization of treatments for orphan and ultra-orphan disorders. post-transcriptional control processes regulate the rate and timing of protein production and are essential to proper cellular function. ptc’s internally-discovered pipeline addresses multiple therapeutic areas, including neuromuscular disorders, oncology and infectious diseases. for more information on the company, please visit our website www.ptcbio.com.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $PTCT News
PTC Therapeutics Submits BLA To FDA For Upstaza - Quick Facts
PTC Therapeutics, Inc. (PTCT) announced the submission of a BLA to the U.S. FDA for Upstaza, a gene therapy for the treatment of ...
PTC Therapeutics Provides Key Regulatory Updates
BLA submitted to FDA for Upstaza™ for the treatment of AADC deficiency - - NDA to be submitted mid-year for Translarna™ based on FDA feedback - SOUTH PLAINFIELD, N.J., March 19, 2024 /PRNewswire/ -- ...
PTC Therapeutics, Inc. (NASDAQ:PTCT) Just Released Its Yearly Earnings: Here's What Analysts Think
Shareholders of PTC Therapeutics, Inc. ( NASDAQ:PTCT ) will be pleased this week, given that the stock price is up ...
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q4 2023 Earnings Call Transcript
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q4 2023 Earnings Call Transcript February 29, 2024 PTC Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.24 EPS, expectations were $0.29.
PTC Therapeutics: Navigating Challenges and Pursuing Growth Amidst Regulatory Hurdles
Analyst Joseph Schwartz of Leerink Partners reiterated a Hold rating on PTC Therapeutics (PTCT – Research Report), with a price target of ...
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH PLAINFIELD, N.J., Feb. 22, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Feb. 15, 2024, the company approved non-statutory stock options to purchase an ...
PTC Therapeutics, Inc.: PTC Therapeutics Provides Key Regulatory Updates
BLA submitted to FDA for Upstaza for the treatment of AADC deficiency - - NDA to be submitted mid-year for Translarna based on FDA feedback - SOUTH PLAINFIELD, N.J., March 19, 2024 /PRNewswire/ -- ...
PTC Therapeutics, Inc. (PTCT) Q4 2023 Earnings Call Transcript
Good afternoon and thank you for joining us today to discuss PTC Therapeutics' fourth quarter and full year 2023 corporate update and financial results. I'm joined today by our Chief Executive ...
PTC Therapeutics Inc PTCT
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q4 2023 Earnings Call Transcript
PTC Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.24 EPS, expectations were $0.29. PTCT isn’t one of the 30 most popular stocks among hedge funds at the end of the ...
PTC Therapeutics Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Loading the latest forecasts...